Jpmorgan Chase & CO Athira Pharma, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATHA
# of Institutions
75Shares Held
23.1MCall Options Held
73.4KPut Options Held
97.8K-
Perceptive Advisors LLC New York, NY5.4MShares$3.46 Million0.41% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$2.02 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$1.05 Million0.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$955,3860.29% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$955,3862.57% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $24.2M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...